(AOF) – Moderna is expected to fall in the pre-market on Wall Street after the Food and Drug Administration announced that the review of the biologics license application (BLA) filed by Moderna for its mRNA-1345 product , the experimental vaccine against respiratory syncytial virus (RSV), would take longer than expected. “Due to administrative constraints”, it should not be completed before the end of May, and not from May 12 as initially planned.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.